Questions About Metastasis-Free Survival in Prostate Cancer

ARTICLES

Questions About Metastasis-Free Survival in Prostate Cancer

MEDSCAPE

PUBLISHED: 08 JANUARY 2019

Last year, a new measure for prostate cancer was used in the regulatory process for the first time. The endpoint of metastasis-free survival (MFS) was used by the Food and Drug Administration (FDA) to approve a new anti-androgen, apalutamide (Erleada, Janssen), and to extend the approval of enzalutamide (Xtandi, Astellas/Pfizer), so that they could be used in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC).